Israel’s MyBiotics (see here previously) is to partner Hadasit – the technology transfer arm of Hadassah Medical Center, to identify gut microbiome-based cancer therapies. They will study up to 100 melanoma patients treated with PD-1/PD-L1 checkpoint inhibitor immunotherapies.

https://www.timesofisrael.com/mybiotics-hadassah-to-study-impact-of-microbiome-on-cancer-therapies/